Nestal

Nestal BioSciences develops medical innovations, specializing in accessible cancer screening. Its product, ClearOne™, is a cytology test for various cancers like cervical and oral, engineered for superior, single-layer slides. ClearOne™ integrates digital and AI for remote expert review and AI-supported clinical decision-making. This approach enhances diagnostic precision, offering screening without expensive equipment for diverse settings.

The company's genesis reflects the critical need for accessible, affordable diagnostic tools worldwide. It was founded by a multidisciplinary team whose extensive experience spans healthcare sales, marketing, cancer cytology, and laboratory operations. This blend of commercial and scientific acumen drives Nestal BioSciences’ dedication to overcoming global healthcare access challenges.

Nestal BioSciences serves healthcare providers and diagnostic laboratories, enabling superior cancer screening. By dismantling cost, equipment, and geographical barriers, the company democratizes access to high-quality care. Its vision is to lead innovative solutions, ensuring advanced diagnostic technology is universally available to patients, ultimately improving global health outcomes.